Latest Commercialisation News

Ionic Rare Earths has announced a $3 million capital raise via convertible notes, aimed at advancing its rare earth projects across multiple continents. The raise, pending shareholder approval, underscores the company’s strategic push into sustainable rare earth extraction and recycling technologies.

Clarity Pharmaceuticals has successfully imaged the first patient in its pivotal Phase III AMPLIFY trial for Cu-SAR-bisPSMA, a next-generation diagnostic agent targeting recurrent prostate cancer. This milestone sets the stage for potential FDA approval and broader clinical adoption.

Green360 Technologies has developed a proprietary low-carbon cement blend using red mud and kaolin, achieving significant reductions in hazardous leachates and competitive strength performance. The company is poised to begin commercial-scale validation with JV partner PERMAcast.

Avecho Biotechnology has received $1.66 million from the Australian Government’s R&D Tax Incentive, reinforcing its commitment to a pivotal Phase III trial for its CBD-based insomnia treatment and accelerating its commercial ambitions.

American Rare Earths has installed groundwater monitoring wells at its Cowboy State Mine, advancing environmental permitting and keeping its rare earth project on track for 2029 production.

ReNerve Limited has gained marketing approval for its NervAlign® Nerve Cuff™ in Bahrain, marking its first regulatory success in the Middle East and opening access to a rapidly expanding regional market.

Aurora Labs has signed a Memorandum of Understanding with Mayman Aerospace to jointly develop 3D-printed micro gas turbines for advanced VTOL aircraft, marking its strategic entry into the U.S. aerospace sector.

Finder Energy has completed a landmark reprocessing of its Ikan 3D seismic data, delivering enhanced imaging that sharpens development plans for the Kuda Tasi and Jahal oil fields. This technical leap forward accelerates the path toward first oil and unlocks new exploration potential within the PSC 19-11 permit.

Neuren Pharmaceuticals posted record 2024 financials driven by DAYBUE royalties and advanced NNZ-2591 into Phase 3 trials, while launching a $50 million share buy-back amid volatile market sentiment.

Lumos Diagnostics has secured Medicare reimbursement for its FebriDx test from a sixth Medicare Administrative Contractor, covering over 85% of US Medicare payment regions. This milestone advances the company’s commercialisation efforts in the US healthcare market.

Future Battery Minerals Ltd has identified significant gold mineralisation at its Miriam Project in Western Australia, setting the stage for a targeted drilling campaign in July 2025. The company’s review of historical data highlights multiple high-potential prospects, including the Forrest zone with continuous gold intercepts over 600 metres.

Solstice Minerals has delivered promising first-ever Reverse Circulation drilling results at its Edjudina Range gold discovery in Western Australia, confirming significant gold mineralisation and setting the stage for accelerated exploration.